Oppenheimer Asset Management Inc. acquired a new stake in shares of Cantel Medical Corp. (NYSE:CMD) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 15,033 shares of the company’s stock, valued at approximately $1,172,000.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Neuberger Berman Group LLC acquired a new stake in Cantel Medical Corp. during the second quarter valued at $96,236,000. Conestoga Capital Advisors LLC acquired a new stake in Cantel Medical Corp. during the second quarter valued at $56,644,000. Bank of New York Mellon Corp acquired a new stake in Cantel Medical Corp. during the second quarter valued at $38,718,000. GW&K Investment Management LLC acquired a new stake in Cantel Medical Corp. during the second quarter valued at $30,121,000. Finally, Public Employees Retirement Association of Colorado acquired a new stake in Cantel Medical Corp. during the second quarter valued at $26,001,000. 84.28% of the stock is owned by hedge funds and other institutional investors.
Shares of Cantel Medical Corp. (NYSE CMD) opened at 82.15 on Friday. The company’s 50-day moving average price is $76.80 and its 200-day moving average price is $76.69. The firm has a market cap of $3.41 billion, a PE ratio of 48.61 and a beta of 1.23. Cantel Medical Corp. has a 52-week low of $68.19 and a 52-week high of $88.81.
Cantel Medical Corp. (NYSE:CMD) last announced its earnings results on Thursday, June 8th. The company reported $0.51 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.51. The firm had revenue of $192.10 million during the quarter, compared to analyst estimates of $193.84 million. Cantel Medical Corp. had a net margin of 9.50% and a return on equity of 17.75%. The firm’s revenue was up 10.6% on a year-over-year basis. Equities analysts expect that Cantel Medical Corp. will post $2.06 earnings per share for the current fiscal year.
A number of research firms recently issued reports on CMD. Needham & Company LLC reissued a “hold” rating on shares of Cantel Medical Corp. in a research report on Friday, September 1st. Zacks Investment Research raised Cantel Medical Corp. from a “sell” rating to a “hold” rating in a research report on Tuesday, August 8th. Sidoti raised Cantel Medical Corp. from a “neutral” rating to a “buy” rating and set a $92.00 price objective for the company in a research report on Wednesday, August 2nd. Finally, Benchmark Co. cut Cantel Medical Corp. from a “buy” rating to a “hold” rating in a research report on Friday, June 9th. Four investment analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $91.67.
In related news, Chairman Charles M. Diker sold 13,000 shares of the company’s stock in a transaction on Monday, June 12th. The shares were sold at an average price of $76.36, for a total value of $992,680.00. Following the completion of the transaction, the chairman now directly owns 3,124,222 shares of the company’s stock, valued at approximately $238,565,591.92. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Chairman Charles M. Diker sold 35,000 shares of the stock in a transaction dated Wednesday, July 12th. The stock was sold at an average price of $75.52, for a total transaction of $2,643,200.00. Following the transaction, the chairman now owns 3,114,520 shares of the company’s stock, valued at $235,208,550.40. The disclosure for this sale can be found here. 14.90% of the stock is currently owned by corporate insiders.
COPYRIGHT VIOLATION NOTICE: This news story was originally reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this news story on another domain, it was stolen and republished in violation of US and international trademark & copyright law. The original version of this news story can be accessed at https://sportsperspectives.com/2017/09/10/15033-shares-in-cantel-medical-corp-cmd-purchased-by-oppenheimer-asset-management-inc.html.
Cantel Medical Corp. Profile
Cantel Medical Corp. is a provider of infection prevention products and services in the healthcare market. The Company’s operating segments include Endoscopy; Water Purification and Filtration; Healthcare Disposables, and Dialysis. Its Endoscopy segment includes medical device reprocessing systems, disinfectants, detergents and other supplies.
Receive News & Ratings for Cantel Medical Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cantel Medical Corp. and related companies with MarketBeat.com's FREE daily email newsletter.